Get to know our clinical trials
Phase 1/2a, first-in-human, open-label clinical trial of BMS-986517 as monotherapy in adult participants with advanced solid tumors.
THIS STUDY IS DESIGNED TO HELP US DETERMINE WHETHER THE STUDY DRUG BMS-986517 WORKS TO TREAT ADVANCED SOLID TUMORS. EXPERTS ARE CONTINUING TO INVESTIGATE BMS-986517 TO LEARN ABOUT ITS SIDE EFFECTS AND EFFICACY. THE STUDY DRUG HAS NOT YET BEEN APPROVED BY THE FOOD AND DRUG ADMINISTRATION (FDA) OR OTHER REGULATORY AGENCIES FOR THE TREATMENT OF ADVANCED SOLID TUMORS OR ANY OTHER MEDICAL CONDITION.
Technical Summary
- PHASE 1/2A, FIRST-IN-HUMAN, OPEN-LABEL STUDY OF BMS-986517 AS MONOTHERAPY IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS.
- Code EudraCT: 2025-522203-23
- Protocol number: CA254-0001
- Promoter: Bristol Myers Squibb
- Molecule/Drug: BMS-986517
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.